Strategy
Merck and Daiichi Sankyo Withdraw Ifinatamab Deruxtecan Application for Small Cell Lung Cancer
The partners said data including results from the IDeate-Lung01 phase 2 trial did not meet FDA requirements for accelerated approval.
AF
By Anna Ferreira
Sep 26, 2026 · 6 min read
Merck and Daiichi Sankyo have voluntarily withdrawn their biologics license application for ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer, the companies said in an announcement issued Friday at 4:30 p.m. Eastern, just after the market close.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.